Diamond Partner
|
|
|
|
Otsuka
Recognizing a critical gap in clinical expertise and research within nephrology, Otsuka took the initiative to pioneer advancements. Otsuka’s commitment remains steadfast in developing groundbreaking therapeutics in nephrology and
other areas. Through enduring perseverance, Otsuka remains focused on offering renewed hope to patients and clinicians.
|
|
 |
| |
|
|
Platinum Partners
|
|
|
| Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish
the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. |
|
 |
| |
|
|
| At Travere Therapeutics we are in rare for life. We come together every day to help patients, families and caregivers as they navigate life with a rare
disease. On this path, we know the need for treatment options is urgent and we work with the rare disease community to identify, develop and deliver life-changing therapies. We continuously seek to understand the diverse perspectives
of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. |
|
 |
| |
|
|
Gold Partner
|
|
|
| Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the
biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. |
|
|
| |
|
|
| Aurinia Pharmaceuticals is a commercial stage biopharmaceutical
company focused on developing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company received FDA approval for their first commercially available drug product
in January 2021. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally. Please visit www.AuriniaLN.com
to learn more about our product. |
|
 |
| |
|
|
Silver Partner
|
|
|
Alnylam Pharmaceuticals Since its founding, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Alnylam is headquartered in Cambridge, MA. For more information, visit www.alnylam.com.
| |  |
| | | |
| Mallinckrodt Pharmaceuticals |
|
 |
| |
|
|
Novartis is reimagining medicine to improve and extend people’s lives.
We deliver high-value medicines that alleviate society’s greatest disease burdens through
technology leadership in R&D and novel access approaches.
We consistently rank among the world’s top companies investing in research and development.
Novartis employs about 14,000 people in the United States.
|
|
 |
| |
|
|
| Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments
that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks
both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN). In addition to IgAN, Vera is evaluating additional diseases where the reduction of
autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BKV, a polyomavirus that can have devastating consequences in certain settings such
as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. |
|
 |
| |
|
|
Bronze Partners
|
|
|
| ANI Pharmaceuticals |
|
 |
| |
|
|
| Alexion - AstraZeneca Rare Disease |
|
 |
| |
|
|
| Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people
by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout
the world. |
|
 |
| |
|
|
| Calliditas Therapeutics |
|
 |
| |
|
|
| CareDX is committed to improving transplant patient outcomes by providing innovative and intelligent solutions throughout the entire patient journey. We are a leading
precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients. |
|
 |
| |
|
|
| Central Florida Kidney Centers |
|
 |
| |
|
|
| CorMedix |
|
 |
| |
|
|
|
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and
nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier
lives.
|
|
 |
| |
|
|
Eurofins Transplant Genomics Meeting the needs of transplant patients and providers is a challenge unlike another. From pre- to post-transplant, we’re equipped with
testing solutions that can do just that. Eurofins Transplant Genomics and Eurofins Ascend come together to provide testing solutions for all stages of the transplant journey.
|
|
 |
| |
|
|
|
Fresenius Medical Care North America. With comprehensive solutions for people living with chronic kidney disease and related conditions, we are working together to improve
the quality of life of every patient, every day. We are transforming healthcare through research, innovation, and compassion.
|
|
 |
| |
|
|
| MedPro Group & Risk-Strategies |
|
 |
| |
|
|
| |
|
|
Natera is a global leader in cfDNA testing. Developed by our trusted legacy in cfDNA, the Prospera transplant assessment test is optimized to be a precise and
reliable tool for early, clinically-meaningful rejection assessment. Renasight, a renal genetics panel, is a comprehensive, accessible genetic test for patients with CKD.
|
|
 |
| |
|
|
| OPKO Renal Developing novel therapies to treat secondary hyperparathyroidism associated with chronic kidney disease. The Renal Division of OPKO Health, Inc.
focuses on developing proprietary products to treat secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). We are proud of our lead nephrology product, Rayaldee® (calcifediol), launched in 2016. In addition,
the Renal Division is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients. OPKO’s expertise in Vitamin D chemistry, biochemistry, metabolism
and physiology, combined with its experience in successfully bringing Vitamin D therapeutics to market uniquely positions the Renal Division to improve the lives of CKD patients. |
|
 |
|
Quanta Dialysis Technologies is committed to making high-quality and cost-effective dialysis accessible to every patient in every setting with its Quanta
Dialysis System - the first and only FDA-cleared device to perform IHD, SLED, and CRRT (CVVHD and SCUF) without any need for bags.
|
|
 |
| |
|
|
|
|
|
Florida Women in Nephrology Chair
FSN President
Print Page